<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909766</url>
  </required_header>
  <id_info>
    <org_study_id>MB123-002</org_study_id>
    <nct_id>NCT00909766</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose and Parallel Arm Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-830216 (Prodrug of BMS-819881) in Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and effect on body weight&#xD;
      and other obesity-related factors of different doses of BMS-830216, compared to placebo. The&#xD;
      study will also determine the amount of BMS-830216 in the blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiograms, physical examinations and clinical laboratory tests</measure>
    <time_frame>Within 2 weeks after study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: to assess the multiple-dose PK of BMS-830216</measure>
    <time_frame>Within 2 weeks of study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: to assess the pharmacodynamic effect of BMS-830216 on body weight and BMI over 4 weeks of therapy</measure>
    <time_frame>Within 2 weeks of study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel G</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel H</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-830216</intervention_name>
    <description>Capsules, Oral, 30 mg, once daily, 28 days</description>
    <arm_group_label>Panel A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-830216</intervention_name>
    <description>Capsules, Oral, 100 mg, once daily, 28 days</description>
    <arm_group_label>Panel B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-830216</intervention_name>
    <description>Capsules, oral, 300 mg, once daily, 28 days</description>
    <arm_group_label>Panel C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-830216</intervention_name>
    <description>Capsules, oral, 600 mg, once daily 28 days</description>
    <arm_group_label>Panel D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-830216</intervention_name>
    <description>Capsules, oral, 1200 mg, once daily, 28 days</description>
    <arm_group_label>Panel E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-830216</intervention_name>
    <description>Capsules, Oral, to be determined, once daily, 28 days</description>
    <arm_group_label>Panel F</arm_group_label>
    <arm_group_label>Panel G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules, Oral, 0 mg, once daily, 28 days</description>
    <arm_group_label>Panel A</arm_group_label>
    <arm_group_label>Panel B</arm_group_label>
    <arm_group_label>Panel C</arm_group_label>
    <arm_group_label>Panel D</arm_group_label>
    <arm_group_label>Panel E</arm_group_label>
    <arm_group_label>Panel H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obese subjects as determined by no clinically significant deviation from normal in&#xD;
             medical history, physical examination, ECGs, and clinical laboratory determinations&#xD;
&#xD;
          -  Body Mass Index (BMI) of 30 to 40 kg/m², inclusive&#xD;
&#xD;
          -  Women who are not of childbearing potential (ie, who are postmenopausal or surgically&#xD;
             sterile) and men, ages 18 to 55, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of organ dysfunction or any clinically significant deviation from normal in&#xD;
             physical examination, vital signs, ECG or clinical laboratory determinations beyond&#xD;
             what is consistent with the target population&#xD;
&#xD;
          -  Female of childbearing potential&#xD;
&#xD;
          -  Sexually active fertile male not using effective birth control method (for example,&#xD;
             condom) if your partners are females of childbearing potential&#xD;
&#xD;
          -  Abnormal blood work results (for example, triglyceride ≥ 400 mg/dL, glucose ≥126 mg/dL&#xD;
             and total cholesterol ≥ 300 mg/dL)&#xD;
&#xD;
          -  High blood pressure (≥160/95 mm Hg)&#xD;
&#xD;
          -  Major surgical procedure within 4 weeks prior to randomization&#xD;
&#xD;
          -  Chronic infections (e.g., HIV [human immunodeficiency virus] or Hepatitis C)&#xD;
&#xD;
          -  Clinically significant history or presence of any of the following conditions: heart,&#xD;
             liver, or kidney disease, neurologic or psychiatric disease, or a previous surgery for&#xD;
             weight loss&#xD;
&#xD;
          -  History of gastrointestinal disease within the past 3 months&#xD;
&#xD;
          -  History of Type I or Type II diabetes in the past 12 months&#xD;
&#xD;
          -  A lifetime history of a suicide attempt or history of any suicidal behavior in the&#xD;
             past month&#xD;
&#xD;
          -  Any clinically significant medical condition that could potentially affect your&#xD;
             participation in the study and/or personal well-being, as judged by the investigator&#xD;
&#xD;
          -  Used grapefruit or grapefruit juice within 1 week prior to randomization&#xD;
&#xD;
          -  Donated blood or blood products to a blood bank, blood transfusion or participated in&#xD;
             a clinical study (except a screening visit) requiring withdrawal of blood within 4&#xD;
             weeks prior to randomization&#xD;
&#xD;
          -  Unable to tolerate oral and/or intravenous (IV) medications&#xD;
&#xD;
          -  Unable to tolerate the puncturing of veins for drawing of blood&#xD;
&#xD;
          -  Prior exposure to BMS-830216&#xD;
&#xD;
          -  History of prior weight loss (for example, gastric bypass or gastric banding) or&#xD;
             gastrointestinal surgery that could impact the absorption of study drug&#xD;
&#xD;
          -  History of a Major Depressive Disorder within the past 2 years&#xD;
&#xD;
          -  Known allergy or hypersensitivity to any component of the study medication&#xD;
&#xD;
          -  History of any significant drug allergies (such as anaphylaxis or hepatotoxicity)&#xD;
&#xD;
          -  Used any oral, injectable or implantable hormonal contraceptive agents (for example,&#xD;
             birth control pills, Depo-Provera, or NuvaRing) within 3 months prior to randomization&#xD;
&#xD;
          -  Used any prescription drugs or over the counter products to control acid (for example,&#xD;
             Prevacid, Mylanta or Rolaids) within 4 weeks prior to randomization&#xD;
&#xD;
          -  Used any prescription drugs, over the counter medications and herbal preparations&#xD;
             within 1 week prior to randomization&#xD;
&#xD;
          -  Taken St. John's Wort within 1 week prior to randomization&#xD;
&#xD;
          -  Taken any investigational drug or placebo (inactive drug) within 4 weeks prior to&#xD;
             randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>May 22, 2009</study_first_submitted>
  <study_first_submitted_qc>May 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <disposition_first_submitted>September 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>October 12, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 4, 2015</disposition_first_posted>
  <last_update_submitted>October 12, 2015</last_update_submitted>
  <last_update_submitted_qc>October 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

